StreetAlpha.app
Home › Stocks › RNTX

Rein Therapeutics, Inc. (RNTX)

Healthcare
$0.36
▼ −10.90%
LAST CLOSE · NOV 17

Rein Therapeutics develops inhaled drug candidates for rare lung diseases, led by a treatment for idiopathic pulmonary fibrosis. It last closed at $0.36 on Nov 17, down 10.90% on the day. In the past 30 days there were 1 dark pool print totaling $188K, the largest $188K.

AI Auto Pilots
Is RNTX in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$0
Net income
−$49.7M
EPS (diluted)
−$1.51
Valuation
Market cap
$30.7M
86.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$943K
At Sep 30
Shareholder equity
$52.8M
Shares outstanding
86.3M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $0$0FY2021FY2022: $0$0FY2022FY2023: $0$0FY2023FY2024: $0$0FY2024FY2025: $0$0FY2025

From RNTX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
—
No ratings in 90 days
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
No firm has rated RNTX in the past 90 days.
Average 12-month target
No price targets on RNTX in the past 90 days.
Latest rating changes
HC Wainwright & Co.Reiterated
Aug 18Buy$8
Maxim GroupInitiated
Jul 20Buy$4
HC Wainwright & Co.Maintained
Jun 1Buy$8
DateFirmActionRatingPrice target
Aug 18HC Wainwright & Co.ReiteratedBuy$8
Jul 20Maxim GroupInitiatedBuy$4
Jun 1HC Wainwright & Co.MaintainedBuy$8
Loading…

Technical Analysis

RNTX · as of the Nov 17 close · updated after every close
Downtrend, oversold

The stock is 70% below its 20 day and 94% below its 50 day average. It is 178% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 24), oversold. The nearest support is the Pivot S1 at $0.32, and the nearest resistance the Pivot at $0.36.

Short trendBearish
Long trendBearish
MomentumWeak
StretchOversold
VolatilityHigh, 22.1%/day
Key levels
$2.1052 week high+483.3%
$0.99200 day average+175.0%
$0.77100 day average+113.9%
$0.6950 day average+91.7%
$0.65Swing high (Oct 21)+80.6%
$0.6020 day average+66.7%
$0.40Pivot R1+11.1%
$0.36Pivot+0.0%
$0.36Last close
$0.32Pivot S1−11.1%
$0.2852 week low−22.2%
Indicators
RSI (14)23.81Oversold below 30Oversold
MACD-0.06Below its signal lineBearish
Stochastic18.5Near the bottom of its rangeOversold
ADX (14)22.3Weak trend
Williams %R-84.5Oversold below −80, overbought above −20Oversold
CCI (20)-274.9Oversold below −100, overbought above 100Oversold
Rate of change−46.6%Change over 10 sessionsBearish
ATR (14)$0.08Typical daily range, 22.1% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for RNTX

What happened before

See how RNTX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Whale Options Flow

90D

No whale options trades in RNTX in the last 90 days.

Loading…

See today’s whale options flow across the market →

Dark Pool

30D
Prints
1
Notional
$188K
Largest print
$188K
Loading…

RNTX Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲24 buying vs 16 selling
  • ●Held by funds +0.3 pts
  • ▲Funds holding +3
  • ●Superinvestors: 1 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding6360+5.0%
In funds' top 10110.0%
Held by funds47.7%47.3%+0.3 pts
New / increased11 / 1319 / 19−36.8%
Reduced / sold out10 / 63 / 6+77.8%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RNTX institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RNTX is in one of them and how their past RNTX trades turned out.

RNTX in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RNTX in an article yet. Here's the latest on the wider market.

About Rein Therapeutics

Rein Therapeutics is a biopharmaceutical company based in Austin, Texas, that develops treatments for rare lung diseases with few effective options. Its lead candidate, LTI-03, is an inhaled peptide being studied for idiopathic pulmonary fibrosis, a progressive lung disease. The company has paused work on its other candidates while it focuses on LTI-03. Its target patients are people living with lung fibrosis and related conditions.

Headquarters
Austin, TX